predxionbio

5 ms·

1. 1.▲
   by predxionbio 6y ago

   There’s a lot of really interesting work left to be done in this area. In our company’s other life we’re involved in CAR-T research, which involves exploiting natural pathways in our immune systems to target them at cancer cells. It’s a sup
2. 2.▲
   by predxionbio 6y ago

   I think we're up against many of the same challenges everyone else (Roche, Abbott, et al.) is up against. At the end of the day if we could all wave a magic wand and fix supply chains we would. Technically, we (the collective diagnosti
3. 3.▲
   by predxionbio 6y ago

   I agree that reliable antibody tests will be a help to policymakers in how they model the continued stay-at-home posture and begin to open things back up. I think the jury is still out on 1. The persistence of the antibody response post-in
4. 4.▲
   by predxionbio 6y ago

   Good sleuthing! As you suspect we functionalize the our sensor surface to specifically bind the virus. We've partnered with a therapeutics company developing highly specific monoclonal mAbs against SARS-CoV-2 which we leverage in our d
5. 5.▲
   by predxionbio 6y ago

   Couple of things at play here. First is we are developing a non-PCR based viral detection test. Many of the molecular tests approved rely on many of the same ancillary components (RNA extraction kits, flocked nasal swabs, viral transport me
6. 6.▲
   by predxionbio 6y ago

   Hi there. We are developing a saliva (e.g., spit in tube) type test. There are a couple of reasons for this including: - supply chain issues with flocked nasal swabs and viral transport media - enable self-sampling limiting healthcare wor
7. 7.▲
   by predxionbio 6y ago

   I'm not familiar with the acronym PSM. Can you expand? Are you familiar with the work of Dr. Chui at UCSF? His group has done some really cool work using mNGS to detect/diagnose emerging/rare infections in critically-ill pati
8. 8.▲
   by predxionbio 6y ago

   Test complexity (sample prep, test workflow) is a real challenge to achieving testing scales at orders of magnitude above what is presently available. We should hopefully have boring old ELISA antigen tests shortly, thanks to Abbott and man
9. 9.▲
   by predxionbio 6y ago

   A regular ELISA/immunoassay is: surface->Ab->protein<-Ab+signal. In school these are taught as "sandwich-assays". Basically you have one antibody to bind your molecule of interest to your substrate, and then another
10. 10.▲
    by predxionbio 6y ago

    Great question. This is one of the implementations we're actually developing. One of the challenges with the implementation of testing on this scale is not necessarily on the technology/assay but on implementation. How do you reas
11. 11.▲
    by predxionbio 6y ago

    Hi, Walker here, one of the PreDxion Bio co-founders. Heres a some more information on the technology underlying the test we are developing: https://pubmed.ncbi.nlm.nih.gov/25790830/ . Unfortunately, up until about a mo
12. 12.▲
    by predxionbio 6y ago

    Hi, Walker here, one of the PreDxion co-founders. Up until recently we've been focused on developing our technogy as a point of care biosensor for us in patients experiencing dysfunctional immune responses (e.g., sepsis, ARDS, and the
13. 13.▲
    by predxionbio 6y ago

    0) From a clinical perspective this is data we are generating on an on going basis. Analytically this is a largely a function of the characteristics of the affinity, specificity of the capture molecule used to capture the target (viral part